Germany-based BioNTech got into the space before the gold rush that was unleashed in September by the news that Akeso and ...

Biotheus’ antibody drug targets PD-L1 and VEGF, a design that’s high on drugmakers’ radars after the success of Summit ...

BioNTech said that BNT327 has the "potential to replace current checkpoint inhibitor standard of care treatments for solid ...

Goldman Sachs upgrades BioNTech to Buy, highlighting the potential of its cancer drug BNT327 and forecasting strong future ...

M uch to the chagrin of investors looking to get rich quickly with a biopharma investment, the drug development cycle is, by ...

The 22nd Annual Winter Lung Cancer Conference, January 31-February 2, 2025, will cover advances in NSCLC and SCLC treatment.

With the end of 2024 approaching, what could be more natural than to figure out the top stocks for the rest of the year?

At the 2024 Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024), held in Houston, USA, from , Akeso Biopharma (9926. HK) presented the mechanism of action (MOA) research findings of ...

But the story could change for Summit in the not-too-distant future. Summit expects to report top-line results in mid-2025 from a late-stage clinical study evaluating ivonescimab as a second-line ...